The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
FountzilasG.DimopoulosA.M.PapadimitriouC.First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol.1998; 9(9): 1031–1034.
2.
LoeschD.RobertN.AsmarL.Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol.2002; 20(18): 3857–3864.
3.
PerezE.SumanV.RowlandK.Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer.2005; 6(5): 425–432.
4.
PegramM.D.LiptonA.HayesD.F.Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol.1998; 16(8): 2659–2671.
5.
SikovW.M.DizonD.S.StrengerR.Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: A Brown University Oncology Group Study. J Clin Oncol.2009; 27(28): 4693–700.
6.
SonkeG.MandjesI.HoltkampM.Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer. Breast J.2013; 19(4): 419–426.
7.
YuK.LiuG.ChenC.Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule. Oncologist.2013; 18(5): 511–517.
8.
ConlinA.K.SeidmanA.D.BachA.Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer.2010; 10(4): 281–287.
9.
RuizM.SalvadorJ.BayoJ.A phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer. Cancer Chemother Pharmacol.2008; 62(6): 1085–1090.
10.
FountzilasG.DafniU.DimopoulosM.A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: A Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat.2009; 115(1): 87–99.
11.
RobertN.Leyland JonesB.AsmarL.Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol.2006; 24(18): 2786–2792.
CalvertA.H.NewellD.R.GumbrellL.A.Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol.1989; 7(11): 1748–56.
14.
CockcroftD.W.GaultM.H.Prediction of creatinine clearance from serum creatinine. Nephron.1976; 16(1): 31–41.
15.
CathomasR.HarleA.MeadG.M.Glomerular filtration rate (GFR) in patients with stage I testicular semi-noma treated with adjuvant carboplatin: A comparison of six formulae compared to a radioisotope gold standard. J Clin Oncol.2007; 25(18 suppl): abstract 15504.
16.
BoumedienF.ArsenaultY.LeTarteN.Impact of weight and creatinine measurements in carboplatin dosing. J Clin Oncol.2012; 30(15 suppl): abstract e13027.
17.
EkhartC.RodenhuisS.SchellensJ.H.M.BeijnenJ.H.HuitemaA.D.R.Carboplatin dosing in overweight and obese patients with normal renal function. Does weight matter?Cancer Chemother Pharmacol.2009; 64(1): 115–122.
18.
HerringtonJ.D.TranH.T.RiggsM.W.Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥ 27 or cachexia. Cancer Chemother Pharmacol.2006; 57(2): 241–247.
19.
DevineB.J.Gentamycin therapy. Drug Intell Clin Pharm.1974; 8: 650–655.
20.
KaagD.Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors. Lung Cancer.2013; 79(1): 54–58.
21.
HerringtonJ.D.TranH.T.RiggsM.W.Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥ 27 or cachexia. Cancer Chemother Pharmacol.2006; 57(2): 241–247.
22.
O'CearbhaillR.New guidelines for carboplatin dosing. Gyn Oncol Group Newsletter.2012; (Spring issue): 5–6.
CheungY.W.CradockJ.C.VishnuvajjalaB.R.FloraK.P.Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Health Syst Pharm.1987; 44(1): 124–130.
25.
KaiserJ.KramerI.Physicochemical stability of diluted trastuzumab infusion solutions in polypropylene infusion bags. Int J Pharmaceut Compound.2011; 15: 515–520.
26.
Herceptin [prescribing information].South San Francisco, CA: Genentech, Inc.; 2013.
27.
HeskethP.J.KrisM.G.GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
MartinM.The severity and pattern of emesis following different cytotoxic agents. Oncology.1996; 53(suppl 1): 26–31.
32.
DuBoisA.VachW.KiechleM.Cramer-GiraudU.MeerpohlH.G.Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis. Oncology1996; 53(suppl 1): 26–31.
33.
GelingO.EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic reevaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
34.
TerreyJ.P.AaproM.S.The activity of granisetron in patients who had previously failed ondansetronantiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
35.
CarmichaelJ.KeizerH.J.CupissolD.MilliezJ.ScheidelP.SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
36.
de WitR.de BoerA.C.vd LindenG.H.StoterG.SparreboomA.VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 85(8): 1099–1101.
37.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
38.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
39.
CornelisonT.L.ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50(2): 147–158.
40.
WeissR.B.DonehowerR.C.WiernikP.H.Hypersensitivity reactions from Taxol. J Clin Oncol.1990; 8(7): 1263–1268.
SmithT.J.KhatcheressianJ.LymanG.H.2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
KintzelP.E.DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
46.
AronoffG.R.BennettW.M.BernsJ.S.BrierM.E.KasbekarN.MuellerB.A.PaskoD.A.SmoyerW.E.Drug Prescribing in Renal Failure.5th ed.Philadelphia: American College of Physicians; 2007.
47.
FloydJ.MirzaI.SachsPerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33(1): 50–67.
48.
KingP.D.PerryM.C.Hepatotoxicity of chemotherapy. Oncologist.2001; 6(2): 162–176.
